STAT+: Biotech FogPharma raises $145 million in anticipation of more clinical trials, pharma partnerships
Oncology startup FogPharma just closed a $145 million Series E round, the company confirmed, reaching…
Category: cancer
Opinion: New federal guidance is hurting cancer patients, especially those in rural areas
I recently started a patient with metastatic triple-positive breast cancer patient on a targeted therapy…
This chemist’s last startup sold for $4 billion. Now investors have poured $173 million into her next act
Jean Cui, a former Pfizer chemist whose last company was sold to Bristol Myers Squibb…
STAT+: Pfizer is about to make a big push in cancer. Will investors listen?
Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer…
Frontline: Hearing aids and longer life span; breast cancer; sleep and good mental health
Study Ties Regular Hearing Aid Use to Longer Life Span Using hearing aids significantly increased…
Ask Dr. Etingin: Falling; Blood Tests
I’ve fallen a few times over the past several months. Is this a normal part…
STAT+: MD Anderson tried — and failed — to resolve research credit dispute between two scientists, new documents show
Early last year, MD Anderson Cancer Center leadership had a problem on their hands: a…
War zone or not, Ukraine seeks to reclaim its role as a hub for clinical trials
In the years leading up to Russia’s invasion, Ukraine had become a burgeoning hub of…
Small study adds to growing hope CAR-T cell therapy could revolutionize autoimmune disease treatment
People with autoimmune disorders don’t usually get to talk about a cure. There’s symptom management,…
Bayer, short on cash, reaches into shareholders’ pockets
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Leading MD Anderson oncologist disputes junior scientist’s claims in lawsuit over research credit
Prominent immunologist and oncologist Padmanee Sharma defended herself in court on Friday against a lawsuit…
STAT+: In ‘major milestone,’ FDA approves first cell therapy for solid tumors
Nearly four decades after its first conception, the first TIL therapy, an immunotherapy that harvests…
Replicate’s srRNA rabies vaccine effective in Phase 1
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Was Pfizer’s “Here’s to Science” commercial during the Super Bowl a winning play or a fumble?
Super Bowl ads are a show within the show, an opportunity for brands and advertising…
Opinion: Former U.S. surgeons general: The U.S. should ban menthol cigarettes
As former U.S. surgeons general, we call on the Biden administration to immediately finalize Food…
STAT+: A junior scientist. A prominent oncologist. Now, a clash at MD Anderson over who gets research credit
Three years ago, Jamie Lin, an early-career nephrologist at MD Anderson Cancer Center, made findings…
STAT+: A looming cancer vaccine test for Gritstone Bio, and pushback about Novartis-MorphoSys
This week, I address pushback I received on my Novartis-MorphoSys column. But first, a preview…
STAT+: Why Novartis is going to walk away from its acquisition of MorphoSys
Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The…
STAT+: Novartis to buy German biotech MorphoSys for $2.9 billion
Novartis said late Monday it has agreed to buy German biotech MorphoSys and its pipeline…
.jpg)
‘Where you live shouldn’t determine how you get cancer’: An oncologist on global disparities
The prediction is dire: Cancer cases around the world are expected to surge 77% by…
We’re naming cancers all wrong, oncology leader says
Naming cancers solely by the organs they originate in is getting a bit old, according…
23andMe breach targeted Chinese, Jewish populations
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: From a small town in Wales, a scientific sleuth has shaken Dana-Farber — and elevated the issue of research integrity
PONTYPRIDD, Wales — The blog post that has shaken the leadership of Boston’s Dana-Farber Cancer…
Eli Lilly overtakes Tesla in market value
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Early detection of pancreatic cancer could get a boost from AI that identifies people at higher risk
Limor Appelbaum has seen too many patients whose first sign of a fatal illness came…
HPV vaccine study finds zero cases of cervical cancer among women vaccinated before age 14
A historic new study out of Scotland shows the real-world impact of vaccines against the…
Another step toward new drugs for Parkinson’s
Want to stay on top of the science and politics driving biotech today? Sign up to get…
‘The response defies belief’: Year of inaction leaves children at risk from bad cancer drugs
A year after an investigation revealed widespread use of a substandard cancer drug, the World…
Ahead of Medicare drug price reform, pharma’s drug pricing has a Streisand effect
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Mammograms are less effective for women with dense breast tissue. Medical experts disagree on what to do about it
Millions of American women over age 40 receive regular mammograms to screen for breast cancer….
Be Aware of Subtle Heart Attack Symptoms
Heart disease is the leading cause of death among women in the United States, and…
.jpg)
Frontline: False-positive mammogram; dementia risk; blockage-related heart attack
False-Positive Mammogram Result May be Warning of Later Breast Cancer Diagnosis Women who get a…
Reduce Inflammation and You May Lower Your Cancer Risk
You may have heard that chronic inflammation is associated with the development of serious diseases,…
STAT+: Gilead’s Trodelvy fails in lung cancer and raises new questions on antibody drug conjugate drugs
Gilead Sciences said Monday that Trodelvy, its “smart-bomb” medicine that combines an antibody with chemotherapy,…
STAT+: In ‘march-in’ rights, some see a tool to lower drug prices. Others see a threat to intellectual property
In the fall of 2020, Robert Sachs was prescribed a medication to treat prostate cancer…
STAT+: Dana-Farber cancer researchers moving to retract one paper, correct others in broad investigation of manipulated data
Scientists at Dana-Farber Cancer Institute, one of the nation’s leading cancer research and treatment centers,…
STAT+: FDA clears AI skin cancer detector for primary care doctors to use
The Food and Drug Administration cleared an AI-powered device for detecting skin cancer on Wednesday,…
STAT+: Hair loss is one of the most hated chemotherapy side effects. A new biotech hopes to prevent it
The chemotherapy Christine Ko was prescribed for her breast cancer is pretty much a guarantee…
The four biotech stories you need to read this morning
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: U.K. sequencing study surfaces new findings about tumor DNA
LONDON — A decade ago, the U.K. launched its 100,000 Genomes Project, a major research…
STAT+: JPM 2024: FogPharma’s new CEO, Mathai Mamman, unveils ‘contrarian’ plan in oncology
SAN FRANCISCO — Six months into his tenure as CEO of cancer startup FogPharma, Mathai…
STAT+: HHS’s Xavier Becerra, once an ‘invisible’ secretary, is racing to cement a clearer legacy
WASHINGTON — He’s been called the “invisible” secretary. So far removed from the White House…
STAT+: The ADC hot streak continues: J&J to buy cancer drug developer Ambrx Biopharma
Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion,…
STAT+: Merck to acquire Harpoon Therapeutics for $680 million
Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs…
Why did Allogene cancel two clinical trials for its off-the-shelf cell therapy?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Illumina chief commercial officer leaves to lead liquid biopsy startup Delfi
Delfi Diagnostics, a startup devising new ways to use routine blood draws to detect early…
STAT+: Allogene to pursue new strategy for development of off-the-shelf cell therapy in blood cancer
Allogene Therapeutics is making unexpected changes to development plans for its off-the-shelf cell therapy for…
STAT+: Veteran biotech entrepreneur Harvey Berger to lead startup Kojin Therapeutics
Veteran biotech entrepreneur Harvey Berger, who has been on the sidelines for the past five…
Quitting alcohol — or even drinking less — reduces risk of oral cavity and esophageal cancer, per new analysis
Reducing or eliminating alcohol consumption reduces the risk of developing oral cavity and esophagus cancers,…
Opinion: Remembering Betty Rollin, who told her breast surgeon that post-operative appearance mattered to her—and other women
Women who had undergone disfiguring surgery for breast cancer, according to one surgeon in the…